9,325 Shares in Kenvue Inc. (NYSE:KVUE) Purchased by Vance Wealth Inc.

Vance Wealth Inc. purchased a new position in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 9,325 shares of the company’s stock, valued at approximately $201,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KVUE. Empirical Finance LLC bought a new stake in Kenvue in the 3rd quarter valued at about $336,000. UniSuper Management Pty Ltd purchased a new position in shares of Kenvue in the third quarter worth about $35,544,000. Citizens Business Bank purchased a new position in shares of Kenvue in the third quarter worth about $2,507,000. Fifth Third Bancorp increased its stake in shares of Kenvue by 35.3% in the fourth quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after purchasing an additional 72,435 shares in the last quarter. Finally, Clearbridge Investments LLC increased its stake in shares of Kenvue by 364.6% in the third quarter. Clearbridge Investments LLC now owns 484,321 shares of the company’s stock worth $9,725,000 after purchasing an additional 380,071 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on KVUE shares. Royal Bank of Canada reduced their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. William Blair assumed coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating for the company. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. Finally, Sanford C. Bernstein assumed coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Kenvue has an average rating of “Hold” and a consensus price target of $24.85.

Kenvue Stock Down 0.8 %

NYSE:KVUE traded down $0.16 during midday trading on Friday, reaching $18.86. 15,454,689 shares of the stock traded hands, compared to its average volume of 13,458,618. The company has a fifty day moving average of $19.84 and a 200 day moving average of $20.13. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The business had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm’s revenue was down 2.7% on a year-over-year basis. As a group, equities research analysts forecast that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.24%. The ex-dividend date of this dividend is Tuesday, May 7th.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.